BRPI0513402A - miméticos de apolipoproteìna a1 e usos dos mesmos - Google Patents

miméticos de apolipoproteìna a1 e usos dos mesmos

Info

Publication number
BRPI0513402A
BRPI0513402A BRPI0513402-1A BRPI0513402A BRPI0513402A BR PI0513402 A BRPI0513402 A BR PI0513402A BR PI0513402 A BRPI0513402 A BR PI0513402A BR PI0513402 A BRPI0513402 A BR PI0513402A
Authority
BR
Brazil
Prior art keywords
apolipoprotein
mimetics
cholesterol levels
plasma cholesterol
provides
Prior art date
Application number
BRPI0513402-1A
Other languages
English (en)
Inventor
William W Bachovchin
Eugenio A Cefali
Original Assignee
Tufts College
Kos Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College, Kos Life Sciences Inc filed Critical Tufts College
Publication of BRPI0513402A publication Critical patent/BRPI0513402A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MIMéTICOS DE APOLIPOPROTEìNA A1 E USOS DOS MESMOS A presente invenção fornece peptidomiméticos obtidos a partir de Apolipoproteína A-I, a qual é útil para influenciar beneficamente parâmetros lipídicos e/ou níveis de colesterol de plasma. A invenção também fornece composições farmacêuticas e métodos de tratamento para níveis elevados de colesterol de plasma.
BRPI0513402-1A 2004-07-16 2005-07-15 miméticos de apolipoproteìna a1 e usos dos mesmos BRPI0513402A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58872204P 2004-07-16 2004-07-16
PCT/US2005/025182 WO2006020040A2 (en) 2004-07-16 2005-07-15 Apolipoprotein a1 mimetics and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0513402A true BRPI0513402A (pt) 2008-05-06

Family

ID=35907926

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513402-1A BRPI0513402A (pt) 2004-07-16 2005-07-15 miméticos de apolipoproteìna a1 e usos dos mesmos

Country Status (12)

Country Link
US (3) US7569546B2 (pt)
EP (1) EP1771473B1 (pt)
JP (1) JP5048486B2 (pt)
KR (1) KR101185609B1 (pt)
CN (1) CN101076541A (pt)
AU (1) AU2005275009B2 (pt)
BR (1) BRPI0513402A (pt)
CA (1) CA2574007A1 (pt)
IL (1) IL180733A (pt)
NO (1) NO20070876L (pt)
TW (1) TWI377066B (pt)
WO (1) WO2006020040A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
AU2005275009B2 (en) * 2004-07-16 2011-12-08 Trustees Of Tufts College Apolipoprotein A1 mimetics and uses thereof
CA2580501A1 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
AU2005314043A1 (en) * 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
JP2008539235A (ja) * 2005-04-29 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症反応によって特徴付けられる病状を処置するためのペプチドおよびペプチド模倣物
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
WO2008021088A2 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
ATE533783T1 (de) * 2006-12-13 2011-12-15 Univ California Potente und selektive mittlersubstanzen von cholesterolefflux
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2704729C (en) 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20110178029A1 (en) * 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) * 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EP2229411B1 (en) * 2007-12-12 2019-02-27 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
CN102395375B (zh) 2009-02-16 2015-01-14 塞伦尼斯医疗控股有限公司 载脂蛋白a-i模拟物
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
WO2011159810A2 (en) * 2010-06-15 2011-12-22 Lawyer Matthew C Compositions and methods for the treatment of atherosclerosis
ES2717455T3 (es) * 2011-02-07 2019-06-21 Cerenis Therapeutics Holding Sa Complejos de lipoproteínas y fabricación y usos de los mismos
EP2983687B1 (en) 2013-03-15 2019-09-04 The Regents of The University of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
FR3026409B1 (fr) * 2014-09-26 2018-03-30 Centre National De La Recherche Scientifique (Cnrs) Procede de criblage de molecules interferentes
WO2016154544A1 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
CA3050106A1 (en) 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apoc-ii mimetic peptides
IL297336A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
CN116322646A (zh) 2020-10-01 2023-06-23 阿比奥尼克斯制药公司 用于治疗眼病的包含基于脂质结合蛋白的复合物的组合物
IL307670A (en) 2021-04-15 2023-12-01 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
CN120344255A (zh) 2022-06-10 2025-07-18 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
AU2024207875A1 (en) 2023-01-13 2025-07-24 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7105635B2 (en) * 2002-06-04 2006-09-12 The University Of Toledo Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents
AU2005275009B2 (en) * 2004-07-16 2011-12-08 Trustees Of Tufts College Apolipoprotein A1 mimetics and uses thereof
CA2580501A1 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
AU2005314043A1 (en) * 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles

Also Published As

Publication number Publication date
TW200612977A (en) 2006-05-01
AU2005275009A1 (en) 2006-02-23
WO2006020040A3 (en) 2006-07-06
TWI377066B (en) 2012-11-21
JP5048486B2 (ja) 2012-10-17
US20100009919A1 (en) 2010-01-14
CN101076541A (zh) 2007-11-21
KR20070095862A (ko) 2007-10-01
NO20070876L (no) 2007-03-30
US20120259091A1 (en) 2012-10-11
US20060069030A1 (en) 2006-03-30
KR101185609B1 (ko) 2012-09-24
EP1771473B1 (en) 2012-12-26
WO2006020040A2 (en) 2006-02-23
EP1771473A2 (en) 2007-04-11
IL180733A0 (en) 2007-06-03
IL180733A (en) 2013-01-31
CA2574007A1 (en) 2006-02-23
US8124580B2 (en) 2012-02-28
AU2005275009B2 (en) 2011-12-08
JP2008506709A (ja) 2008-03-06
US7569546B2 (en) 2009-08-04

Similar Documents

Publication Publication Date Title
BRPI0513402A (pt) miméticos de apolipoproteìna a1 e usos dos mesmos
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
EP2452683A3 (en) Methods for treating atherosclerosis
EA200700924A1 (ru) Соединения ряда дибензиламина и их производные
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
EP2522721A3 (en) Modified lecithin-cholesterol acyltransferase enzymes
EP2319925A3 (en) Therapeutic uses of inhibitors of RTP801
EP2402443A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
NO20082075L (no) Anti-hyperkolesterolemiske forbindelser
TW200736253A (en) Pyridopyrazine derivatives and their use
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
CR9528A (es) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2008011611A3 (en) Compounds and compositions as itpkb inhibitors
WO2006138163A3 (en) Anti-hypercholesterolemic compounds
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2012057492A3 (ko) 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
DE602005010270D1 (de) Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
WO2007005672A3 (en) Treatment and prevention of respiratory diseases and conditions
WO2006047312A3 (en) COMPOSITIONS AND METHODS FOR MODULATING PGC-1β TO TREAT LIPID-RELATED DISEASES AND DISORDERS
WO2007071658A3 (en) Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
EA200801815A1 (ru) Дибензиламиносоединения и производные

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.